<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="131" ids="25107">Magnesium</z:chebi> (Mg) deficiency increases genomic instability and Mg intake has been reported to be inversely associated with a risk of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>This study was designed to determine whether organo-Mg in drinking water suppresses <z:mp ids='MP_0001845'>inflammation</z:mp>-associated colon <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> in mice </plain></SENT>
<SENT sid="2" pm="."><plain>Male Crj: CD-1 mice were initiated with a single i.p. injection of azoxymethane (AOM, 10mg/kg body weight) and followed by a 1 week exposure to <z:chebi fb="0" ids="34674">dextran sulfate</z:chebi> <z:chebi fb="199" ids="26708">sodium</z:chebi> (DSS, 1.5%, w/v) in drinking water to induce colonic <z:hpo ids='HP_0002664'>neoplasms</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>They were then given the drinking water containing 7, 35 or 175 p.p.m </plain></SENT>
<SENT sid="4" pm="."><plain>organo-Mg for 13 weeks </plain></SENT>
<SENT sid="5" pm="."><plain>The chemopreventive efficacy of organo-Mg was determined 16 weeks after the AOM exposure </plain></SENT>
<SENT sid="6" pm="."><plain>Administration with organo-Mg at <z:hpo ids='HP_0000001'>all</z:hpo> doses caused a significant inhibition of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> development (P &lt; 0.01 and P &lt; 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>Especially, the highest dose of organo-Mg significantly suppressed the occurrence of <z:hpo ids='HP_0000001'>all</z:hpo> the colonic pathological lesions (mucosal <z:mpath ids='MPATH_579'>ulcer</z:mpath>, <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, <z:mpath ids='MPATH_270'>adenoma</z:mpath> and <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>) </plain></SENT>
<SENT sid="8" pm="."><plain>Organo-Mg also significantly reduced the number of mitoses/anaphase bridging, as well as proliferation of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Additionally, at week 4, organo-Mg lowered the <z:chebi fb="5" ids="33699">messenger RNA</z:chebi> expression of certain proinflammatory cytokines, such as interleukin-1β, interleukin-6, interferon-γ and inducible nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase in the lesion-free colorectal mucosa at week 4 but increased the Nrf-2 messenger <z:chebi fb="40" ids="33697">RNA</z:chebi> expression </plain></SENT>
<SENT sid="10" pm="."><plain>Our findings that organo-Mg inhibits <z:mp ids='MP_0001845'>inflammation</z:mp>-related mouse colon <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> by modulating the proliferative activities and <z:mp ids='MP_0008866'>chromosomal instability</z:mp> of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and suppressing colonic <z:mp ids='MP_0001845'>inflammation</z:mp> may suggest potential use of organo-Mg for clinical chemoprevention trials of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> in the inflamed colon </plain></SENT>
</text></document>